Pretomanid

Names: PA-824
Chemical class: Nitroimidazole
Background

Pretomanid is a nitroimidazole, a class of novel anti-bacterial agents. Pretomanid has been developed by TB Alliance and is approved by the US FDA to treat XDR-TB or treatment-intolerant/non-responsive MDR-TB, in combination with bedaquiline and linezolid, as part of the BPaL regimen. Early in pretomanid's development, it was known as "PA-824."

More information on pretomanid and BPaL can be found here

Additional resources:

Peer-reviewed publications

 

Clinical Trials

 

Phase 2 (Advanced)

Regimen Associations

This compound has appeared in the following regimens:

Trial Associations

This compound has appeared in the following trials: